Realheart hires investment advisor in the UAE

Press release, March 14, 2022

Realheart has partnered with an experienced investment advisor in the UAE, Dr Abdulla Khalfan Saeed Alkindi, who will help the company meet the high level of interest in the product and the company in the Middle East.

Realheart, who is developing the world's first four-chamber artificial heart, has received considerable international attention. There is particularly strong interest in the Middle East. This is partly due to the attention given to the inventor and founder of Realheart, Azad Najar, who himself was born and raised in Iraqi Kurdistan. Another contributing factor is that heart failure affects many in the region – and often at a younger age than in the West – while few transplants are performed.

Dr Azad Najar is regularly invited to speak at various medical conferences and, for example, he recently attended the International Conference of Pharmacy and Medicine (ICPM) in Sharjah, where the organizers are already highlighting his attending next year's conference too, set to take place in January 2023. During his visit, Najar participated in several meetings with various stakeholders, including Dr Alkindi, who is a board member of the Sharjah Research Technology and Innovation Park, where the ICPM is held. He will from now on assist the company in liaising with individuals and organizations interested in the Realheart TAH.

''We're seeing a lot of interest, from doctors and researchers as well as potential investors and future partners in this region, and we need to have someone present there to help us both manage that and see how best to capitalize on it. That's where Dr Alkindi has both the knowledge needed and the network of contacts," said Realheart's CEO Ina Laura Perkins.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.